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Hypothesis: The effectiveness of extrapleural pneumonectomy
(EPP) to extend quality-adjusted survival in malignant pleural me-
sothelioma within multimodality treatment should be proven in a
randomized controlled trial if this radical surgery is to be regarded
as the standard of care. The question was whether randomization to
surgery versus no surgery would be possible.
Methods: The Mesothelioma and Radical Surgery trial was planned
to randomize 50 patients to test feasibility. There was a two-stage
consent process. At first consent, the patients who were possible
candidates for radical surgery were registered into the trial for
completion of assessment and staging. All received platinum-based
chemotherapy. If still eligible, they completed a second consent to
be randomized to have either EPP followed by radical hemithorax
radiotherapy or to have continued best care.
Results: Patients were recruited through 11 collaborating centers in
the United Kingdom. One hundred twelve potentially eligible pa-
tients gave informed consent to enter the registration phase and
undergo chemotherapy. One died, 27 progressed, five were inoper-
able, four were treated off trial, and 18 withdrew either during or
after chemotherapy but before final review. Additionally six were
deemed inoperable at review after completing chemotherapy and
one more patient withdrew. The remaining 50 were randomized; 24
to EPP and 26 to continued best care.
Conclusions: In this study, 50/112 (45%) of patients entering the
evaluation and induction phase of the trial went on to be random-
ized. We have shown that this randomization between surgery and
no surgery is feasible. This was the primary aim of the Mesotheli-
oma and Radical Surgery trial.
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The asbestos-related cancer, malignant mesothelioma is amajor health problem internationally.1 The European ep-
idemic is expected to reach its peak within the next decade2
and an eventual total of about 250,000 mesothelioma deaths
is predicted.3 Britain has the highest incidence of mesotheli-
oma worldwide, with more than 2000 deaths in 2006, the
great majority being malignant pleural mesothelioma (MPM).
The highest incidence is in British men born between 1945
and 1950. About one in 150 of all men and more than one in
20 carpenters of this generation will develop mesothelioma in
the United Kingdom.4 Worldwide trends are difficult to
predict, as reliable mesothelioma death rates are not yet
available for many countries including Russia, China, and
India, but we do know that there are many instances of
uncontrolled asbestos use, and there is likely to be an increase
in the disease in the third world.
Mesothelioma is a diffuse cancer, spreading along the
pleura. The aim of extrapleural pneumonectomy (EPP) is
macroscopic disease clearance by removal of all the parietal
and visceral pleura as well as the lung. In contemporary
practice, the pericardium and the diaphragm are also removed
and replaced with prosthetic material. When the operation
was first devised in the 1970s, perioperative mortality was
30%5 and few surgeons adopted the operation. Several re-
ports between 1999 and 2004 reported lower mortality (av-
erage 6%) and claimed improved long-term survival, but only
*Guy’s and St Thomas’ Hospital, London, United Kingdom; †Glenfield
Hospital, University Hospitals of Leicester, Leicester, United Kingdom;
‡The Royal Marsden Hospital, London, United Kingdom; §St James’
Hospital, Dublin, Ireland; St James’ Hospital, Leeds, United Kingdom;
¶King’s College London and Guy’s and St Thomas’ Hospitals, London,
United Kingdom; #Clinical Trials and Statistics Unit, Institute of Cancer
Research, Sutton, United Kingdom; **South West Dementia and Neu-
rodegenerative Diseases Research Network (DeNDRoN), Avon Wilt-
shire Mental Health Partnership NHS Trust, Bath, United Kingdom; and
††London School of Hygiene and Tropical Medicine and The Institute of
Cancer Research, London, United Kingdom.
This study is registered as an International Standard Randomised Controlled
Trial number ISRCTN95583524 and funded by Cancer Research UK
(CRUK04/003).
Address for Correspondence: Tom Treasure, MD, MS, FRCS, FRCP, Clinical
Operational Research Unit, UCL (Department of Mathematics), 4 Taviton
Street, London WC1H 0BT, United Kingdom. E-mail: tom.treasure@gmail
Copyright © 2009 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/09/0410-1254
Journal of Thoracic Oncology • Volume 4, Number 10, October 20091254
when the operation was part of multimodality therapy com-
bined with induction or postoperative chemotherapy and
commonly radical postoperative radiotherapy.6–10 Modern
radiotherapy techniques after EPP allow higher doses to be
given to the whole hemithorax but results reported recently
are not good, and while there is local control extrathoracic
recurrence is a major problem.11
The benefit of multimodality therapy may have been
overestimated. Selection of patients for radical surgery ex-
cluded those with more advanced disease, and reports were
typically of those who have completed all components of
multimodality therapy. No information was provided in any
report concerning the denominator from which the operated
patients were drawn.12 There are circumstances in which
treatment and effect are so closely linked mechanistically and
chronologically that randomized comparison is unneces-
sary,13 but this is certainly not the case for EPP, and most
thoracic surgeons are reluctant to undertake such radical
surgery in the absence of better evidence of improvement
in survival and/or quality of life. Rates of local progression
and distant metastasis after diagnosis vary widely, and in
the absence of randomized trials the effects of adding EPP
to the other components of multimodality therapy cannot
be assessed.14
Randomized trials in surgery are infrequently per-
formed,15 and it was predicted that randomization would not
be possible. The Mesothelioma and Radical Surgery (MARS)
trial was therefore initiated to test the feasibility of random-
izing patients in the knowledge that the study was not
powered to prove effectiveness of EPP over other manage-
ment. This report describes recruitment to the MARS feasi-
bility trial, which began in October 2005 and closed in
November 2008.
METHODS
The MARS trial was a multicenter randomized con-
trolled trial of patients with MPM in which EPP followed by
radiotherapy was compared with no EPP. The target was to
randomize 50 patients, who had completed chemotherapy,
between the radical intervention combing surgery and radio-
therapy, and local standard care. The accrual rate was to be
monitored as well as compliance with randomized allocation,
toxicity, quality of life, and survival.
A screening log was requested from all the centers but
was not mandatory. MARS had a two-stage consent process
(Figure 1). Patients had to have disease limited to the pleura
based on computerized tomography and be fit to undergo
chemotherapy, radical surgery by EPP, and radical radiother-
apy. At first consent, eligible patients were registered to
receive three cycles of platinum-based chemotherapy accord-
ing to the MARS protocol, but the final commitment to
randomization to EPP versus no EPP remained open. Staging
was then completed with mediastinoscopy and, where avail-
able, positron emission tomography. Patients with histologi-
cally positive mediastinal nodes were excluded. After receiv-
ing three cycles of chemotherapy, all patients were then
restaged with computerized tomography and any uncertain-
ties resolved by further investigation. Fitness for pneumonec-
tomy was assessed using British Thoracic Society criteria
(predicted postoperative forced expiratory volume in one
second 40%, echocardiography indicating mean pulmo-
nary artery pressure 35 mm Hg). Fitness for radiotherapy
required that the contralateral kidney should have suffi-
cient function in the event of radiation damage on the
treated side (normal blood urea and creatinine, glomerular
filtration rate, dimercaptosuccinic acid scan if necessary).
The MARS “virtual” multidisciplinary team (vMDT)
comprised a subset of the Trial Management Group and when
possible the referring clinician. A vMDT teleconference was
held for each patient considered eligible by the referring
clinician after clinical data and imaging reports had been
circulated to vMDT members. Patients were informed of the
vMDT decision, and those still deemed eligible were invited
to sign a second written informed consent to be randomized
to EPP and radical radiotherapy or to no EPP.
Patients were entitled to withdraw at any stage with-
out giving a reason. Patients who declined randomization
because they only wanted to be considered for surgery
were referred, with their clinical work up to that point, to
appropriately experienced surgeons outside of the MARS
protocol.
FIGURE 1. Mesothelioma and Radical Surgery (MARS) trial
patient progress flowchart.
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RESULTS
Between October 2005 and November 2008, 11 United
Kingdom centers (Figure 2) screened more than 300 patients.
Screening logs are available for 261 patients. One hundred
twelve patients were registered after the first informed con-
sent. By the end of the registration phase, one had died, 27
had progressed, five were inoperable, four were treated off
trial, and 18 withdrew either during or after chemotherapy but
before final review. Additionally six were deemed inoperable
at review after completing chemotherapy and one more pa-
tient withdrew after review. The remaining 50 were random-
ized: 24 to EPP and 26 to no EPP.
Because patients did not have to give a reason for
withdrawing, reasons were not always explicit. For the 19 of
43 patients (Figure 2) who did not want to register (the first
written consent) 10 did not want to be randomized. We
believe that eight did not want to be considered for surgery,
and we know that one did not want to travel to the treatment
center. Of the 18 who withdrew between the first and second
written consent, 11 decided that they did not want to have
EPP, six gave no reason, and one wanted treatment at the
local hospital.
At close of recruitment, five surgical centers and 10
radiotherapy centers (Tables 1 and 2) were active. Methods
for collection of complex surgical and radiotherapy data have
been successfully established, and evaluating suitability for
surgery by the MARS vMDT has proved feasible. Clinical
FIGURE 2. Patient flow from screening to rando-
misation.
TABLE 1. Active Surgical Centres
EPP No EPP Totals
Guy’s Hospital, London 10 11 21
Glenfield Hospital, Leicester 10 10 20
St. James’ University Hospital, Leeds 3 3 6
Royal Brompton Hospital, London 1 1
Northern General Hospital, Sheffield 1 1 2
24 26 50
EEP, extrapleural pneumonectomy.
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details and survival statistics will be published 1 year after
completion of treatment of the 50th randomized patient.
DISCUSSION
MARS was a difficult study to implement because of
the large difference between the treatments in the two groups,
and it was not known whether sufficient patients would
consent to randomization to make an adequately powered
trial possible. The feasibility study has shown that this radical
randomization can be achieved, with 50 of the 112 patients
(45%) who entered the study for evaluation were eventually
randomized. Our most important finding is that a reasonable
proportion of eligible patients are willing to be randomized
between surgery and no further treatment even for an oper-
ation as radical as EPP.
The two-stage consent was deemed necessary in the
trial design because the preparatory phase, including surgical
staging by mediastinoscopy, would not have been a usual
management for patients not undergoing EPP. It produced an
unanticipated benefit: two-stage consent enabled patients to
enter the study without being committed to the subsequent
surgical randomization. This probably increased recruitment,
as the interval of at least 3 months between consent to enter
the study and consent to surgical randomization allowed time
for measured reflection and removed pressure from both
patients and doctors. It had been predicted that randomization
to such a trial was impossible by several experienced re-
searchers; we now know that this commonly made assertion
is not evidence based and can be contested.
An incidental but striking effect of involvement in the
trial was on clinical practice. Efficiency and confidence in
diagnosis, staging, and clinical decision making seemed to
improve markedly in participating clinical centers, to the
benefit of patients.
During the course of the trial, the primary surgical ques-
tion has evolved. Although MARS was recruiting, several major
institutions published retrospective analyses suggesting that EPP
offers no advantage over less radical lung-sparing operations,
such as pleurectomy and decortication.16–20 In the absence of
randomized trials, however, such data cannot provide reliable
evidence on the role of surgery in MPM. The protocol for the
next trial has not yet been decided, but the inclusion of a
nonsurgical arm is essential because there is a serious doubt
surrounding claims for effectiveness of surgery,21 which
cannot be resolved by follow-up studies comparing one
form of operation with another. We have shown that
randomization to radical surgical alternatives is possible
but larger trials would be needed to determine whether any
type of surgery is better or worse than none for the large
number of patients who will develop mesothelioma during
the next 40 years.
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